Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Other Non-Current Assets: 2010-2025

Historic Other Non-Current Assets for Arrowhead Pharmaceuticals (ARWR) over the last 15 years, with Sep 2025 value amounting to $1.4 million.

  • Arrowhead Pharmaceuticals' Other Non-Current Assets fell 69.01% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year decrease of 69.01%. This contributed to the annual value of $1.4 million for FY2025, which is 69.01% down from last year.
  • Arrowhead Pharmaceuticals' Other Non-Current Assets amounted to $1.4 million in Q3 2025, which was up 2.66% from $1.4 million recorded in Q2 2025.
  • Arrowhead Pharmaceuticals' Other Non-Current Assets' 5-year high stood at $4.5 million during Q3 2024, with a 5-year trough of $210,000 in Q4 2022.
  • Over the past 3 years, Arrowhead Pharmaceuticals' median Other Non-Current Assets value was $1.4 million (recorded in 2025), while the average stood at $1.8 million.
  • In the last 5 years, Arrowhead Pharmaceuticals' Other Non-Current Assets surged by 2,023.81% in 2024 and then crashed by 69.66% in 2025.
  • Quarterly analysis of 5 years shows Arrowhead Pharmaceuticals' Other Non-Current Assets stood at $273,000 in 2021, then decreased by 23.08% to $210,000 in 2022, then increased by 10.48% to $232,000 in 2023, then soared by 1,228.88% to $3.1 million in 2024, then slumped by 69.01% to $1.4 million in 2025.
  • Its Other Non-Current Assets stands at $1.4 million for Q3 2025, versus $1.4 million for Q2 2025 and $1.3 million for Q1 2025.